PHARMAMAR HA ACTUALIZADO FASE III LAGOON LURBINECTEDIN Y SE RETRASA SU CONCLUSIÓN HASTA ABRIL 2026.
24 mayo 2017
PharmaMar announces that on May 24, 2017 has entered into a liquidity agreement (the “Liquidity Agreement”) with MEDIACIÓN BURSÁTIL, SOCIEDAD DE VALORES, SA (the “Financial Intermediary”), in order to favor liquidity of transactions and the regularity of trading of their shares.
‹
›
Inicio
Ver versión web